COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
902.6 DKK | +2.01% | +3.12% | +29.29% |
10:19pm | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
10:02pm | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
902.6 DKK | +2.01% | +3.12% | 567B | ||
55.85 USD | -0.80% | -0.32% | 10.19B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.29% | 567B | |
+34.00% | 664B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B | |
-11.01% | 145B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk owner refiles U.S. application for approval of Catalent deal